BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BEBT-209 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BEBT-209\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07544056-9086@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:BEBT-209: Phase 2/3 readout est. (NCT07544056)
DESCRIPTION:BEBT-209\, phase 2/3\, Breast Cancer.\nStudy: A Study of BEBT-2
 09 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Tripl
 e-Negative Breast Cancer\nEstimated primary completion: June 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bebt-209#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07544056
URL:https://assetmemo.bio/drug/bebt-209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
